@dansfera: The uncomfortable truth about commercial IRB funding is laid bare here. When payment is tied directly to sponsor approvals, does ethical oversight become negotiable? This discussion cuts straight to the heart of industry transparency, questioning whether a Private Equity-owned IRB is ultimately beholden to trial ethics or its fiduciary duty to investors. Where does the line get crossed into pure rubber stamping? A necessary listen for anyone invested in the integrity of medical research. #ClinicalTrials #IRB #Bioethics #MedTech #PrivateEquity